Vol 7, Supplement 4 (April 26, 2018): Translational Cancer Research

Editorial

Neurological complications of anti-PD-1 antibodies: shall we be more concerned?
Kyrillus S. Shohdy, Omar Abdel-Rahman
Translational Cancer Research  
2018;
7
(Suppl 4)
:S436-S438
.
ZATT, TDP2, and SUMO2: breaking the tie that binds TOP2 to DNA
Steven R. Hall, Kerry Brennan Goralski
Translational Cancer Research  
2018;
7
(Suppl 4)
:S439-S444
.
Evolutionary acquired robustness and vulnerability in cancer genome: negligible negative selection in carcinogenesis
Kazuki Kumada, Jun Yasuda
Translational Cancer Research  
2018;
7
(Suppl 4)
:S445-S448
.
Fibroblast growth factor signaling as a bypass mechanism of the androgen receptor pathway: new perspectives for castrationresistant prostate cancer
Ihsan Y. El-Sayed, Francis Vacherot, Stéphane Terry
Translational Cancer Research  
2018;
7
(Suppl 4)
:S449-S452
.
PD-1 in cancer: Dr. Jekyll and Mr. Hyde
Marion Alcantara, Melania Tesio, Vahid Asnafi
Translational Cancer Research  
2018;
7
(Suppl 4)
:S453-S456
.
Myc and Ras, the Bonnie and Clyde of immune evasion
Sílvia Casacuberta-Serra, Laura Soucek
Translational Cancer Research  
2018;
7
(Suppl 4)
:S457-S459
.
Targeting HSP90 in malignant gliomas: onalespib as a potential therapeutic
Naomi Lomeli, Daniela A. Bota
Translational Cancer Research  
2018;
7
(Suppl 4)
:S460-S462
.
The emerging landscape of lncRNAs in diabetic nephropathy
Xiaoyun He, Chibin Pu, Chunlin Ou, Suxian Zhou
Translational Cancer Research  
2018;
7
(Suppl 4)
:S463-S465
.
A human mutated gene is guillotining spermatozoa
Jesús del Mazo, Miguel A. Brieño-Enríquez, Eduardo Larriba
Translational Cancer Research  
2018;
7
(Suppl 4)
:S466-S468
.
Hypofractionated whole breast irradiation is cost-effective—but is that enough to change practice?
Apar Gupta, Nisha Ohri, Bruce G. Haffty
Translational Cancer Research  
2018;
7
(Suppl 4)
:S469-S472
.
Adjuvant chemotherapy in patients with newly diagnosed non-co-deleted anaplastic gliomas—a new standard
Kelly Lauren Braun, David Marc Peereboom
Translational Cancer Research  
2018;
7
(Suppl 4)
:S473-S475
.
Editorial: fate mapping of human glioblastoma reveals an invariant stem cell hierarchy
Sabrina P. Koh, Agadha C. Wickremesekera, Tinte Itinteang, Swee T. Tan
Translational Cancer Research  
2018;
7
(Suppl 4)
:S476-S479
.
Duloxetine for AI-associated joint pain in breast cancer patients
Moe Tsuda, Masakazu Toi
Translational Cancer Research  
2018;
7
(Suppl 4)
:S480-S483
.
Temozolomide—the jack of all gliomas? Reviewing the interim results of the CATNON trial for 1p/19q non-co-deleted anaplastic glioma
Mateo Ziu, Jeffrey I. Traylor
Translational Cancer Research  
2018;
7
(Suppl 4)
:S484-S487
.
When the inhibitor is turned into stimulator: novel aspects in T cell engineering
Felicitas Rataj, Stefan Endres, Sebastian Kobold
Translational Cancer Research  
2018;
7
(Suppl 4)
:S488-S490
.
There must be another way—disulfiram and cancer treatment: editorial on “Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4”
Hovav Nechushtan, Tamar Peretz
Translational Cancer Research  
2018;
7
(Suppl 4)
:S491-S494
.
Disulfiram combats cancer via crippling valosin-containing protein/p97 segregase adaptor NPL4
Nan Ding, Qianzheng Zhu
Translational Cancer Research  
2018;
7
(Suppl 4)
:S495-S499
.
How many pancreatic cysts are out there and how to best manage them?
Victor Ciofoaia, Nadim G. Haddad, Jill P. Smith
Translational Cancer Research  
2018;
7
(Suppl 4)
:S500-S505
.
The guanine nucleotide exchange factor VAV2 as a new prognostic parameter in adrenocortical carcinoma
Deborah Cosentini, Sandra Sigala, Elisa Saba, Elisa Roca, Alfredo Berruti
Translational Cancer Research  
2018;
7
(Suppl 4)
:S506-S509
.
Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma
David C. Binder, Erik Ladomersky, Alicia Lenzen, Lijie Zhai, Kristen L. Lauing, Sebastian D. Otto-Meyer, Rimas V. Lukas, Derek A. Wainwright
Translational Cancer Research  
2018;
7
(Suppl 4)
:S510-S513
.
Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer
Kazuhiro Araki, Yasuo Miyoshi
Translational Cancer Research  
2018;
7
(Suppl 4)
:S514-S518
.
Role of enhancer activation in pancreatic cancer metastasis
Paloma Cejas, Marta Mendiola, Jaime Feliu
Translational Cancer Research  
2018;
7
(Suppl 4)
:S519-S520
.
Circular RNA FBXW7: implication in glioma tumorigenesis
Luka Bolha, Damjan Glavač
Translational Cancer Research  
2018;
7
(Suppl 4)
:S521-S524
.
Improving hormonal therapy: to extend, to intermit, or to readjust expectations?
Iris Noordhoek, Esther Bastiaannet, Cornelis J. H. van de Velde
Translational Cancer Research  
2018;
7
(Suppl 4)
:S525-S527
.

Letter to the Editor

Is there still room for anti-angiogenic agents in small cell lung cancer?
Matteo Brighenti, Marcello Tiseo
Translational Cancer Research  
2018;
7
(Suppl 4)
:S528-S529
.

Perspective

PD-1/PD-L1 pathway inhibition to restore effector functions in exhausted CD8+ T cells: chances, limitations and potential risks
Priya Veluswamy, Dunja Bruder
Translational Cancer Research  
2018;
7
(Suppl 4)
:S530-S537
.

Disclosure:

This supplement was published without any sponsorship or funding.